Sensus Healthcare, Inc. (NASDAQ:SRTS) Short Interest Update

Sensus Healthcare, Inc. (NASDAQ:SRTS) was the recipient of a large decline in short interest during the month of February. As of February 28th, there was short interest totalling 845,600 shares, a decline of 28.3% from the February 13th total of 1,180,000 shares. Based on an average daily trading volume, of 325,600 shares, the short-interest ratio is presently 2.6 days. Approximately 6.2% of the company’s stock are short sold.

Sensus Healthcare Price Performance

NASDAQ:SRTS traded down $0.11 during trading hours on Tuesday, hitting $4.75. 55,418 shares of the company were exchanged, compared to its average volume of 307,627. Sensus Healthcare has a 52-week low of $3.09 and a 52-week high of $9.33. The company’s 50 day moving average price is $5.98 and its 200-day moving average price is $6.64. The stock has a market capitalization of $78.35 million, a price-to-earnings ratio of 11.86 and a beta of 1.28.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.01). Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%. On average, equities analysts predict that Sensus Healthcare will post 0.32 earnings per share for the current year.

Analyst Upgrades and Downgrades

SRTS has been the topic of several research analyst reports. HC Wainwright boosted their target price on shares of Sensus Healthcare from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Monday, February 10th. Lake Street Capital dropped their target price on shares of Sensus Healthcare from $18.00 to $13.00 and set a “buy” rating on the stock in a research report on Tuesday, March 11th.

Institutional Trading of Sensus Healthcare

Several institutional investors and hedge funds have recently bought and sold shares of the business. Squarepoint Ops LLC lifted its stake in Sensus Healthcare by 175.5% during the 4th quarter. Squarepoint Ops LLC now owns 85,677 shares of the company’s stock valued at $593,000 after acquiring an additional 54,576 shares during the period. Man Group plc lifted its stake in shares of Sensus Healthcare by 34.0% in the 4th quarter. Man Group plc now owns 59,338 shares of the company’s stock valued at $411,000 after purchasing an additional 15,059 shares during the period. OMERS ADMINISTRATION Corp acquired a new position in shares of Sensus Healthcare in the 4th quarter valued at $381,000. Millennium Management LLC lifted its stake in shares of Sensus Healthcare by 256.6% in the 4th quarter. Millennium Management LLC now owns 85,329 shares of the company’s stock valued at $590,000 after purchasing an additional 61,403 shares during the period. Finally, BNP Paribas Financial Markets acquired a new position in shares of Sensus Healthcare in the 4th quarter valued at $47,000. 25.30% of the stock is currently owned by institutional investors and hedge funds.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.